Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products
Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Overall investment in the US facility is estimated around US$50 million
Subscribe To Our Newsletter & Stay Updated
